Why Benitec Biopharma Inc.’s (BNTC) Stock Is Down 8.68%
As of Wednesday, September 23, Benitec Biopharma Inc.’s BNTC share price has dipped by 8.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Commentary & Analysis
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Down 5.42%
As of Tuesday, September 15, Benitec Biopharma Inc.’s BNTC share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Up 6.91%
As of Tuesday, July 28, Benitec Biopharma Inc.’s BNTC share price has surged by 6.91%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Down 5.04%
As of Friday, July 10, Benitec Biopharma Inc.’s BNTC share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Benitec Biopharma Inc.’s (BNTC) Stock Is Up 6.26%
As of Tuesday, June 23, Benitec Biopharma Inc.’s BNTC share price has surged by 6.26%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $282.9 | $208.8 | 32% |
|
| Shares Out (Mil) | 49.4 | 53.9 | 47% |
|
| Institutional Ownership | 95.2% | 93.1% | 67% |
|
| Float (Mil) | 18.5 | 41.4 | 27% |
|
| Beta | 0.27 | 0.95 | 16% |
|
| Avg Daily Volume (000s) | 213 | 614 | 46% |
|
| Price Change (52-week) |
(49.0%) | 45.3% | 21% |
|
| Growth | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (26.8%) | (10.2%) | 16% |
|
| EPS (5yr) | 55.3% | 15.7% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (46.2%) | (15.7%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($46) | ($44) | 17% |
|
| EPS (TTM) | ($0.978) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($33) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $205 | $174 | 26% |
|
| Valuation | BNTC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.58 | 2.09 | 45% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BNTC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (32.3%) | (47.2%) | 16% |
|
| ROE | (33.2%) | (54.2%) | 19% |
|
| Liabilities to Assets | 3.1% | 29.1% | 1% |
|
| F-Score | 3 | 2 | 18% |
|
Benitec Biopharma Inc. did not pass any screens on 10/16/2026.
